Treatment of Protein S Deficiency in Triple Antiphospholipid Positive Syndrome
When Protein S deficiency occurs alongside triple antiphospholipid positive syndrome, the clinical picture carries specific therapeutic implications that set it apart from other thrombophilic presentations.
This protocol addresses Protein S deficiency in the context of triple antiphospholipid positive syndrome — a high-risk thrombotic combination in which the anticoagulant choice is not empiric. Unlike venous thromboembolism of unknown origin, where the final diagnosis may take weeks to establish, this presentation has a defined therapeutic requirement from the outset.
A specific anticoagulant — warfarin — is part of the mandatory approach in this scenario. The complete structured regimen, including all decision points, is available via the link below.
References
DOI: 10.1186/s12959-026-00861-w
Unless a patient is diagnosed with triple antiphospholipid positive syndrome (for which warfarin treatment is mandatory), the choice of the anticoagulant drug for VTE of an unknown origin is empiric, given that the final (clinical, instrumental, and/or laboratory) diagnosis is achieved weeks after beginning therapy.